Claims
- 1. A compound selected from the group consisting of a compound of the formula ##STR33## wherein R.sub.1 is selected from the group consisting of --CN, --NO.sub.2 and halogen, R.sub.2 is --CF.sub.3, or halogen, --A--B--is ##STR34## X is --O-- or --S--, R.sub.3 is a) alkyl, alkenyl and alkynyl of up to 6 carbon atoms uninterrupted or interrupted with oxygen or unoxidized or oxidized sulfur, phenyl and phenylalkyl of 1 to 6 alkyl carbon atoms and all substituted with at least one member of the group consisting of --SH, acyloxy of an aliphatic carboxylic acid up to 7 carbon atoms, --phenyl, --O--phenyl, --O--phenalkyl, halo --S--phenyl, with the sulfur being unoxidized or oxidized to sulfone or sulfoxide, or heterocyclic of 3 to 6 ring members and containing at least one heteroatom selected from the group consisting of oxygen, sulfur and nitrogen, phenyl and phenalkyl being unsubstituted or substituted with a member of the group consisting of halogen, --CF.sub.3, alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl and alkynyloxy, b) trialkylsilyl with alkyl of 1 to 6 carbon atoms, c) acyl and acyloxy of an organic carboxylic acid of 1 to 7 carbon atoms, Y is selected from the group consisting of .dbd.O, .dbd.S and .dbd.NH and their non-toxic, pharmaceutically acceptable acid addition salts.
- 2. A compound of claim 1 wherein Y is oxygen.
- 3. A compound of claim 1 wherein --A--B-- is ##STR35## and X is sulfur.
- 4. A compound of claim 3 wherein R.sub.3 is alkyl of 1 to 4 carbon atoms unsubstituted or substituted with a --OH or methoxy.
- 5. A compound of claim 1 wherein R.sub.1 is --CN or halogen.
- 6. A compound of claim 1 wherein R.sub.1 wherein R.sub.1 is chlorine.
- 7. A compound of claim 1 wherein --A--B-- is ##STR36## and R.sub.3 is alkyl or alkenyl of up to 6 carbon atoms unsubstituted or substituted or optionally interrupted by oxygen or uninterrupted or oxidized sulfur or unoxidized or substituted or unsubstituted aralkyl.
- 8. A compound of claim 7 wherein R.sub.3 is alkyl of 1 to 6 carbon atoms unsubstituted or substituted by at least one member of the group consisting of halogen, --OH, --O acyl, carboxy, carboxy esterified with alkyl, a heterocycle, O-aralkyl and unoxidized or oxidized S-aryl with the aryl unsubstituted or substituted with at least one member of the group consisting of halogen and alkoxy.
- 9. A compound of claim 8 wherein R.sub.3 is alkyl of 2 to 4 carbon atoms substituted by a member selected from the group consisting of chlorine, ethoxycarbonyl, tert-butoxy carbonyl, cyclopentyloxycarbonyl, unoxidized or oxidized 4-fluorophenylthio, morpholino, phenylmethoxy, triphenylmethoxy and methylsulfonyloxy.
- 10. A compound of claim 1 wherein Y is --O-- except the compounds wherein the --A--B-- group is ##STR37## in which is oxygen and, R.sub.2 is halogen or trifluoromethyl and R.sub.1 is nitro or halogen.
- 11. A compound of the formula ##STR38## wherein R.sub.1, R.sub.2 and Y have the definitions of claim 1, --A--.sub.i --B.sub.i is ##STR39## Y is oxygen or sulfur and R'.sub.3 is R.sub.3 with any reactive functions protected.
- 12. A compound of claim 1 selected from the group consisting of 4-(5-oxo-2-thioxo-3,4,4-trimethyl-1-imidazolidinyl)-2-(trifluoromethyl)-benzonitrile, 4-(4,4-dimethyl-5-oxo-2-thioxo 1-imidazolidinyl)-2-(trifluoromethyl)-benzonitrile, 4-[4,4-dimethyl-3-(2-hydroxyethyl)-5-oxo-2-thioxo-1-imidazolidinyl-2-(trifluoromethyl)-benzonitrile, 3-(3,4-dichlorophenyl)-2-thioxo-1,5,5-trimethyl-4-imidazolidinone, 1-(4-nitro-3-(trifluoromethyl)-phenyl-3,4,4-trimethyl-2,5-imidazolidinedione, 4-[[4,5-dihydro 4,4-dimethyl-5-oxo-2-(phenylmethyl)-thio]-1H-imidazol-1-yl]-2-(trifluoromethyl) benzonitrile, 4[4,4-dimethyl 3-(2-hydroxyethyl) 5-oxo 2-thioxo 1-imidazolidinyl]2-(trifluoromethyl) benzonitrile, 4-(4,4-dimethyl 3-(4-hydroxybutyl) 5-oxo 2-thioxo 1-imidazolidinyl) 2-(trifluoromethyl) benzonitrile, 3-(4-cyano 3-trifluoromethyl) phenyl) 5,5-dimethyl 2,4-dioxo 1-imidazolidinebutanoic acid and 4-(4,4-dimethyl 2,5-dioxo 3-(4-hydroxybutyl) 1-imidazolidinyl) 2-(trifluoromethyl) benzonitrile.
- 13. An anti-androgenic composition comprising an anti-androgenically effective amount of at least one compound of claim 1 and an inert pharmaceutical carrier.
- 14. A composition of claim 13 wherein the active compound is selected from the group consisting of 4-(5-oxo-2-thioxo-3,4,4-trimethyl-1-imidazolidinyl)-2-(trifluoromethyl)-benzonitrile, 4-(4,4-dimethyl-5-oxo-2-thioxo 1-imidazolidinyl)-2-(trifluoromethyl)-benzoitrile, 4-[4,4-dimethyl-3-(2-hydroxyethyl)-5-oxo-2-thioxo-1-imidazolidinyl-2-(trifluoromethyl)-benzonitrile, 3-(3,4-dichlorophenyl)-2-thioxo-1,5,5-trimethyl-4-imidazolidinone, 1-(4-nitro-3-(trifluoromethyl)-phenyl-3,4,4-trimethyl-2,5-imidazolidinedione, 4-[[4,5-dihydro 4,4-dimethyl-5-oxo-2-(phenylmethyl)-thio]-1H-imidazol-1-yl]-2-(trifluoromethyl) benzonitrile-4[4,4-dimethyl 3-(2-hydroxyethyl) 5-oxo 2-thioxo 1-imidazolidinyl]2-(trifluoromethyl) benzonitrile, -4-(4,4-dimethyl 3-(4-hydroxybutyl) 5-oxo 2-thioxo 1-imidazolidinyl) 2-(trifluoromethyl) benzonitrile-3-(4-cyano 3-trifluoromethyl) phenyl) 5,5-dimethyl 2,4-dioxo 1-dioxo 3-(4-hydroxybutyl) 1-imidazolidinyl) 2-(trifluoromethyl) benzonitrile.
- 15. A method of inducing anti-androgenic activity in warm-blooded animals comprising administering to warm-blooded animals an anti-androgenically effective amount of at least one compound of claim 1.
- 16. A method of claim 15 wherein Y is oxygen.
- 17. A method of claim 15 wherein R.sub.1 is --CN or halogen.
- 18. A method of claim 15 wherein R.sub.1 is chlorine.
- 19. A method of claim 13 wherein the active compound is selected from the group consisting of 4-(5-oxo-2-thioxo-3,4,4-trimethyl-1-imidazolidinyl)-2-(trifluoromethyl)-benzonitrile, 4(4,4-dimethyl-5-oxo-2-thioxo 1-imidazolidinyl)-2-(trifluoromethyl)-benzoitrile, 4-[4,4-dimethyl-3-(2-hydroxyethyl)-5-oxo-2-thioxo-1-imidazolidinyl-2-(trifluoromethyl)-benzonitrile, 3-(3,4-dichlorophenyl)-2-thioxo-1,5,5-trimethyl-4-imidazolidinone, 1-(4-nitro-3-(trifluoromethyl)-phenyl-3,4,4-trimethyl-2,5-imidazolidinedione,4-[[4,5-dihydro 4,4-dimethyl-5-oxo-2-(phenylmethyl)-thio]-1H-imidaozl-1-yl]-2-(trifluoromethyl) benzonitrile-4[4,4-dimethyl 3-(2-hydroxyethyl) 5-oxo 2-thioxo 1-imidazolidinyl]2-(trifluoromethyl) benzonitrile, -4-(4,4-dimethyl 3-(4-hydroxybutyl) 5-oxo 2-thioxo 1-imidazolidinyl) 2-(trifluoromethyl) benzonitrile-3-(4-cyano 3-trifluoromethyl) phenyl) 5,5-dimethyl 2,4-dioxo 1-imidazolidinebutanoic and acid and 4-(4,4-dimethyl 2,5-dioxo 3-(4-hydroxybutyl) 1-imidazolidinyl) 2-(trifluoromethyl) benzonitrile.
Priority Claims (2)
Number |
Date |
Country |
Kind |
91 00185 |
Jan 1991 |
FRX |
|
92 08431 |
Jul 1992 |
FRX |
|
PRIOR APPLICATION
This application is a division of U.S. patent application Ser. No. 064,257 filed May 18, 1993, now U.S. Pat. No. 5,411,981 which is a continuation-in-part of U.S. patent application Ser. No. 819,910, filed Jan. 9, 1992, now abandoned.
US Referenced Citations (7)
Divisions (1)
|
Number |
Date |
Country |
Parent |
64257 |
May 1993 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
819910 |
Jan 1992 |
|